Reported Earnings • Apr 10
Full year 2024 earnings released: ₩1,254 loss per share (vs ₩1,576 loss in FY 2023) Full year 2024 results: ₩1,254 loss per share. Revenue: ₩8.50b (down 26% from FY 2023). Net loss: ₩46.9b (loss widened 11% from FY 2023). New Risk • Apr 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩13.5b (US$9.24m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 38% per year over the past 5 years. Market cap is less than US$10m (₩13.5b market cap, or US$9.24m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). 공시 • Mar 19
Clinomics Inc. announced that it has received KRW 5.5 billion in funding On March 18, 2025, Clinomics Inc. closed the transaction. The company will now issue KRW 5,500,000,000. The transaction will include participation from new investor Dominate Co., Ltd. 공시 • Mar 18
Clinomics Inc., Annual General Meeting, Mar 31, 2025 Clinomics Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 31, doho-gil, samnam-eup, ulju-gun, ulsan South Korea New Risk • Feb 11
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩13.4b (US$9.25m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 38% per year over the past 5 years. Market cap is less than US$10m (₩13.4b market cap, or US$9.25m). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding). New Risk • Dec 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩16b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 38% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (₩20.1b market cap, or US$14.4m). New Risk • Nov 09
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (₩25.3b market cap, or US$18.1m). New Risk • Sep 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (₩26.5b market cap, or US$19.8m). 공시 • May 30
Clinomics Inc. has completed a Follow-on Equity Offering in the amount of KRW 999.999932 million. Clinomics Inc. has completed a Follow-on Equity Offering in the amount of KRW 999.999932 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 742,942
Price\Range: KRW 1346
Transaction Features: Subsequent Direct Listing 공시 • May 19
Clinomics Inc. has filed a Follow-on Equity Offering in the amount of KRW 999.999932 million. Clinomics Inc. has filed a Follow-on Equity Offering in the amount of KRW 999.999932 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 742,942
Price\Range: KRW 1346
Transaction Features: Subsequent Direct Listing 공시 • May 18
Clinomics Inc. announced that it has received KRW 4 billion in funding On May 17, 2024, Clinomics Inc. closed the transaction. New Risk • Nov 30
New major risk - Revenue and earnings growth Revenue has declined by 77% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 77% over the past year. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩70.2b market cap, or US$54.4m). New Risk • Oct 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩81.8b market cap, or US$60.7m). New Risk • Sep 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩92.7b market cap, or US$69.5m). New Risk • Jun 15
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Revenue has declined by 77% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (₩90.4b market cap, or US$70.7m). Reported Earnings • Mar 26
Full year 2022 earnings released: ₩768 loss per share (vs ₩1,214 profit in FY 2021) Full year 2022 results: ₩768 loss per share (down from ₩1,214 profit in FY 2021). Revenue: ₩23.1b (down 58% from FY 2021). Net loss: ₩10.2b (down 164% from profit in FY 2021). Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₩9,290, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 21% over the past year. 공시 • Dec 02
Clinomics Inc. announced that it expects to receive KRW 2.99999694 billion in funding Clinomics Inc. announced a private placement of 381,679 convertible registered preferred stock at an issue price of KRW 7,860 for gross proceeds of KRW 2,999,996,940 on December 1, 2022. The transaction will included participation from TS 2018-12 M&A Fund. The preferred stock bear dividend rate 1.0% per year. Each preferred stock is convertible into one common shares. The conversion request period is starting from December 17, 2023 till November 17, 2027. The securties to be issued may be participatory or non-participating, cumulative or non-cumulative. The transaction was approved by the board of directors of the company. The transaction is expected to close on December 16, 2022. The securities to be issued in the transaction will be subject to a 1 year hold period from date of issuance. The company will issue securities through 3rd party allocation increase method. Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improved over the past week After last week's 27% share price gain to ₩6,980, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 19x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past year. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩5,640, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 21x in the Biotechs industry in South Korea. Total loss to shareholders of 51% over the past year. Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment improved over the past week After last week's 15% share price gain to ₩9,180, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past year. Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment improved over the past week After last week's 19% share price gain to ₩7,960, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 52% over the past year. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩6,500, the stock trades at a trailing P/E ratio of 4.9x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total loss to shareholders of 58% over the past year. Reported Earnings • Nov 16
Third quarter 2021 earnings released: EPS ₩354 (vs ₩289 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩17.2b (up ₩16.3b from 3Q 2020). Net income: ₩4.63b (up ₩7.77b from 3Q 2020). Profit margin: 27% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. 공시 • Feb 22
Clinomics Inc., Annual General Meeting, Mar 24, 2021 Clinomics Inc., Annual General Meeting, Mar 24, 2021, at 11:00 Korea Standard Time.